In 2025, the global drugs market reached approximately US$ 1,688.14 billion. It is expected to grow to US$ 1,790.05 billion in 2026 and is projected to reach nearly US$ 3,034.63 billion by 2035, registering a compound annual growth rate (CAGR) of 6.04% during the forecast period.
Download Customized Sample For Free:
https://www.towardshealthcare.com/download-sample/5713
This growth reflects increasing healthcare demand, innovation in drug development, and a rising burden of chronic diseases worldwide.
Why Is the Global Drugs Market Growing?
Several structural and medical factors are driving this expansion:
1. Rising Chronic Diseases
Conditions such as cancer, diabetes, cardiovascular diseases, autoimmune disorders, and neurological illnesses are increasing globally. Aging populations, lifestyle changes, and environmental factors contribute to sustained medication demand.
2. Oncology Dominance
Cancer treatments remain the largest revenue-generating segment in the pharmaceutical market. Immunotherapies and targeted therapies are now standard treatments across multiple cancer types.
3. Biologics and Specialty Drugs
Biologic drugs, including monoclonal antibodies and advanced immunotherapies, now represent a significant share of top-selling medicines. These therapies typically command higher prices due to their complexity and clinical value.
4. Innovation in R&D
Artificial intelligence, genomic research, and precision medicine are improving drug discovery timelines and enabling more personalized treatment approaches.
5. Emerging Market Expansion
Countries across Asia-Pacific, Latin America, and the Middle East are increasing healthcare investments, expanding access to branded and specialty drugs.
Top-Selling Drugs in 2024: Commercial Leaders
Below are the top revenue-generating drugs based on 2024 sales performance and their U.S. patent expiry timelines:
| SN | Drug | Company | Sales (2024) $B | US Patent Expiry |
|---|---|---|---|---|
| 1 | Keytruda | Merck | 30 | 2028 |
| 2 | Eliquis | BMS, Pfizer | 13 | 2026 |
| 3 | Darzalex | Johnson & Johnson | 12 | 2029 |
| 4 | Opdivo | BMS | 9 | 2028 |
| 5 | Gardasil | Merck | 8.5 | 2028 |
| 6 | Xtandi | Astellas, Pfizer | 8 | 2027 |
| 7 | Farxiga | AstraZeneca | 8 | 2026 |
| 8 | Ocrevus | Roche | 7.5 | 2030 |
| 9 | Cosentyx | Novartis | 6 | 2029 |
| 10 | Trulicity | Eli Lilly | 5 | 2027 |
These products represent some of the most commercially successful therapies globally, primarily in oncology, cardiovascular disease, autoimmune disorders, and metabolic conditions.
Source: Towards Healthcare
In-Depth Analysis of Leading Drugs
Keytruda (Merck) – The Oncology Leader
With approximately $30 billion in 2024 sales, Keytruda is the highest-selling drug globally. It is an immune checkpoint inhibitor used across multiple cancer indications, including lung cancer, melanoma, and head and neck cancers.
Its success is driven by:
-
Broad label expansions
-
Strong clinical outcomes
-
Use in both advanced and early-stage cancers
However, its U.S. patent expiry in 2028 presents a major revenue risk. Biosimilar competition could significantly reduce sales after loss of exclusivity unless lifecycle management strategies succeed.
Eliquis (Bristol Myers Squibb & Pfizer) – Cardiovascular Giant
Generating around $13 billion in 2024, Eliquis is a leading anticoagulant used to prevent stroke and treat blood clots.
Its patent expiry in 2026 makes it one of the most immediate “patent cliff” risks among blockbuster drugs. Generic competition could substantially impact revenue, although brand loyalty and payer positioning may cushion the decline.
Darzalex (Johnson & Johnson) – Multiple Myeloma Specialist
Darzalex earned approximately $12 billion in 2024 and remains a leading treatment in blood cancers. Its patent protection until 2029 provides relatively longer revenue stability compared to several peers.
Opdivo (BMS) – Immunotherapy Competitor
Opdivo, another immune checkpoint inhibitor, generated about $9 billion in 2024. It competes directly with Keytruda in several cancer indications.
Patent expiry in 2028 places it within the same competitive pressure window as other oncology leaders.
Other High-Impact Products
-
Gardasil (Merck) – HPV vaccine generating strong global revenue with demand tied to vaccination programs.
-
Xtandi (Astellas/Pfizer) – A major prostate cancer therapy with solid global uptake.
-
Farxiga (AstraZeneca) – A diabetes drug expanding into heart failure and kidney disease indications.
-
Ocrevus (Roche) – A top therapy for multiple sclerosis with longer patent life until 2030.
-
Cosentyx (Novartis) – A key immunology drug used for psoriasis and arthritis.
-
Trulicity (Eli Lilly) – A GLP-1 therapy for diabetes, competing in a fast-growing metabolic market.
The Patent Cliff: A Major Industry Challenge
Between 2026 and 2029, many top-selling drugs will lose U.S. patent protection. This phenomenon, often called the “patent cliff,” allows generic and biosimilar manufacturers to enter the market at significantly lower prices.
Historically, blockbuster drugs can lose 50–80% of revenue within a few years after patent expiry.
Pharma companies are responding with:
-
Reformulated versions (e.g., subcutaneous or extended-release versions)
-
Combination therapies
-
New indication approvals
-
Strategic acquisitions
-
Strong pipeline development
Competitive Landscape: Top Pharmaceutical Companies
The global market remains concentrated among a handful of multinational pharmaceutical giants:
Merck
Driven by Keytruda and Gardasil, Merck remains one of the most oncology-focused leaders.
Bristol Myers Squibb
Strong presence in immuno-oncology and cardiovascular drugs.
Pfizer
Broad portfolio spanning vaccines, oncology, and cardiovascular products.
Johnson & Johnson
Diversified across oncology, immunology, and other therapeutic segments.
Roche
A leader in biologics, particularly oncology and neurology.
Novartis
Focused on innovative medicines and specialty therapies.
AstraZeneca
Expanding rapidly in oncology, respiratory, and metabolic segments.
Eli Lilly
Strengthening its position in diabetes and metabolic treatments.
Access our exclusive, data-rich dashboard dedicated to the therapeutic area sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Checkout Drugs Market Report Now at: https://www.towardshealthcare.com/checkout/5713
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
About the Author
